Sakar Healthcare Ltd (SAKAR) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Sakar Healthcare Ltd on NSE and BSE, with an AI summary of each filing.
Sakar Healthcare Limited has informed the Exchange about Transcript
Transcript · 02 Nov 2026, 9:46 pm
Sakar Healthcare Reports Strong Q2 FY27 Results Driven by Oncology Expansion Sakar Healthcare reported robust Q2 FY27 performance, with operational revenue rising 52% YoY to INR 8,741.61 lakhs, EBITDA jumping 114% YoY to INR 2,434.53 lakhs (margin at 28% vs. 20%), and PAT surging 149% YoY to INR 1,130.69 lakhs. Management targets over 35% revenue growth and expects overall quarterly revenue to cross INR 100 crores from Q3. In oncology, API backward integration and upcoming global commercializations are projected to expand EBITDA margins toward 35% over the next two years.
Sakar Healthcare Limited has informed the Exchange about Link of Recording
Audio / Video · 27 Oct 2026, 10:19 pm
Sakar Healthcare Releases Q2FY27 Earnings Conference Call Audio Recording Sakar Healthcare Limited has released the audio recording of its investor conference call conducted on 27th Oct'26. The call discussed the company's unaudited financial results for the quarter and half-year ended 30th Sep'26 (Q2 and H1FY27). The recording is accessible on the company's official website, and the management confirmed that the written transcript of the earnings call will be submitted to the stock exchanges and uploaded online in due course.
Sakar Healthcare Limited has informed the Exchange about Investor Presentation
Investor Presentation · 26 Oct 2026, 7:34 pm
Sakar Healthcare Reports Strong Q2FY27 Results Driven by Oncology Expansion Sakar Healthcare posted robust Q2FY27 consolidated performance, with revenue rising 52% YoY to INR 8,741.61 lakhs and PAT surging 149% YoY to INR 1,130.69 lakhs. EBITDA jumped 114% YoY to INR 2,434.53 lakhs, expanding margins by 800 bps to 28%. Growth is driven by its integrated, EU-GMP-approved Bavla oncology facility, executing 69 oncology contracts with commercial supplies underway across regulated markets. The company holds 22 granted global Marketing Authorisations, 33 active tech transfers, and targets over 100 overseas contracts within two years.
Sakar Healthcare Limited has informed the Exchange regarding a press release dated October 26, 2026, titled "Press Release - Consolidated and Standalone Unaudited Financial Results for the quarter and half year ended September 30, 2026".
Press Release · 26 Oct 2026, 7:30 pm
Sakar Healthcare Reports Strong Q2FY27 Results With 149% YoY PAT Surge Sakar Healthcare reported robust Q2FY27 consolidated performance, with revenue from operations growing 52% YoY to ₹8,741.61 lakhs. EBITDA jumped 114% YoY to ₹2,434.53 lakhs with margins expanding 800 bps to 28%, while PAT surged 149% YoY to ₹1,130.69 lakhs (13% margin), driven by favorable oncology mix and operational leverage. For H1FY27, revenue reached ₹16,038.86 lakhs and PAT stood at ₹2,159.18 lakhs. Growth was supported by commencement of commercial supplies from its EU-GMP approved oncology site, 69 executed contracts, and regulatory advancements.
Sakar Healthcare Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
Outcome · 23 Oct 2026, 5:47 pm
Sakar Healthcare Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Lakh) ■ Revenue: 8,742 (+51.9% YoY | +19.8% QoQ) ■ EBITDA: 2,435 (+114.4% YoY | +14.6% QoQ) ■ EBITDA Margin (%): 27.8 (+812 bps YoY | -127 bps QoQ) ■ PAT: 1,131 (+149.1% YoY | +9.9% QoQ) ■ EPS (INR): 5.08 (+150.2% YoY | +10.0% QoQ)
Sakar Healthcare Limited has informed the Exchange about Schedule of meet
Intimation · 27 Oct 2026, 3:00 pm
Sakar Healthcare Schedules Q2 and H1FY27 Earnings Conference Call Sakar Healthcare Limited will host an earnings conference call for analysts and investors on 27th Oct'26 at 3:00 PM IST to discuss its financial performance for Q2 and H1FY27. Key management participants representing the company include Bikramjit Ghosh, VP of Strategy & Business Development, and Bharat Soni, Company Secretary.
SAKAR HEALTHCARE LIMITED has informed the Exchange about Board Meeting to be held on 23-Oct-2026 to consider and approve the Quarterly Unaudited Financial results of the Company for the period ended September 2026 and Other business.
Intimation · 23 Oct 2026, 5:30 am
Sakar Healthcare Board Meeting on 23rd Oct'26 for Q2 Results Sakar Healthcare Limited has informed the stock exchange that its Board of Directors will meet on 23rd Oct'26. The board will consider, approve, and take on record the company's unaudited quarterly financial results for the period ended Sep'26, alongside other general business matters.
To consider and approve the financial results for the period ended September 30, 2026 and other business matters
Intimation · 23 Oct 2026, 5:30 am
Sakar Healthcare Board to Consider Q2 Results on 23rd October 2026 Sakar Healthcare Limited has scheduled a meeting of its Board of Directors on 23rd Oct'26 to consider and approve the unaudited financial results for the quarter ended 30th Sep'26, alongside other business matters. In accordance with SEBI Insider Trading Regulations and the company's Code of Conduct, the trading window for designated persons remains closed until 48 hours following the declaration of the financial results.
Sakar Healthcare Limited has informed the Exchange about Sakar s global export model expands with oncology products
Others (Uncategorized) · 14 Oct 2026, 7:31 pm
Sakar Healthcare Expands Global Oncology Footprint and Secures Key Regulatory Approvals Sakar Healthcare is accelerating its oncology exports across the EU, UK, APAC, Canada, and LatAm, securing 22 Marketing Authorisations out of 190 submissions globally. The company achieved 11 site-variation approvals with major MNCs and received two CEP approvals out of seven applications for its 21 in-house APIs to support vertical integration. Commercial supplies have commenced from its EU GMP-approved oncology FDF facility. Additionally, management clarified that proposed domestic MRP caps on oncology drugs will not impact operations, as business is export-skewed and trade margin caps leave manufacturer realizations unaffected.
Sakar Healthcare Limited has informed the Exchange about Certificate under Regulation 74 (5) of the SEBI (Depositories and Participants) Regulations, 2018 for the Quarter ended 30th Sept 2026
Others (Uncategorized) · 09 Oct 2026, 6:58 pm
Sakar Healthcare Submits Dematerialisation Compliance Certificate for Quarter Ended 30th Sep'26 Sakar Healthcare Limited submitted its compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended 30th Sep'26. Issued by its Registrar and Share Transfer Agent, MUFG Intime India Private Limited, the certificate confirms that securities received for dematerialisation during the quarter were duly processed, listed on stock exchanges, and physical share certificates were mutilated and cancelled within prescribed regulatory timelines.
Sakar Healthcare Limited has informed the Exchange regarding Appointment of M/s. Kashyap R. Mehta & Partners as Secretarial Auditors of the Company for the term of 5 years w.e.f. September 22, 2026.
Change in Management · 22 Sept 2026, 10:06 pm
Sakar Healthcare Appoints Kashyap R. Mehta & Partners as Secretarial Auditor Sakar Healthcare Limited announced that shareholders approved the appointment of M/s. Kashyap R. Mehta & Partners, Practising Company Secretaries, as the company's Secretarial Auditors at its 22nd AGM on 22nd Sep'26. The appointment is for a term of five consecutive years covering FY 2026-27 through FY 2030-31, following prior board approval on 24th Jul'26. The Ahmedabad-based firm brings over four decades of expertise in corporate governance, SEBI regulations, capital markets, and corporate legal advisory.
Sakar Healthcare Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on September 22, 2026. Further, the company has informed the Exchange regarding voting results.
Annual General Meeting · 22 Sept 2026, 9:59 pm
Sakar Healthcare Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 22, 2026
Annual General Meeting · 22 Sept 2026, 7:21 pm
Sakar Healthcare Limited has informed the Exchange about Schedule of meet on 18th Sept., 2026
Intimation · 14 Sept 2026, 6:10 pm
Sakar Healthcare Schedules Physical Plant Visit and Management Interaction with Analysts Sakar Healthcare Limited announced an in-person interaction with analysts and investors scheduled for 17th Sep'26 and 18th Sep'26. The physical meeting will comprise a plant visit and direct management interaction, strictly discussing publicly available information with no unpublished price-sensitive information shared.
Sakar Healthcare Limited has informed the Exchange about Schedule of meet on 17th Sept., 2026
Intimation · 14 Sept 2026, 6:07 pm
Sakar Healthcare Schedules Plant Visit and Investor Meet on Sep'26 Sakar Healthcare Limited has scheduled an in-person group interaction with analysts and investors on 17th Sep'26 and 18th Sep'26. The physical meeting will comprise a plant visit alongside interactions with company management. Discussions will strictly rely on publicly available information without the disclosure of unpublished price-sensitive data.
Sakar Healthcare Limited has informed the Exchange about Sakar receives 14 oncology product new approvals in the EU (Europe), UK & Canada with 7 business partners
Others (Uncategorized) · 01 Sept 2026, 5:34 pm
Sakar Healthcare Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 22, 2026
Annual General Meeting · 27 Aug 2026, 6:53 pm
Sakar Healthcare Limited has informed the Exchange about Transcript of Con-Call.
Transcript · 03 Aug 2026, 8:45 pm
Sakar Healthcare Q1 FY27 Results Driven by Strong Oncology and Export Growth Sakar Healthcare reported robust Q1 FY27 results with revenue up 38% YoY to INR 7,297 lakhs and PAT surging 120% YoY to INR 1,028 lakhs. EBITDA grew 67% to INR 2,125 lakhs, with margins improving to 29%. The oncology division was a key driver, generating INR 33 crores, including INR 6.5 crores from exports. Management expects oncology export revenue to reach INR 60-70 crores in FY27, driven by tech transfers and MA-based sales. The company's Bavla facility is projected to support INR 800-1,000 crores in revenue.
Sakar Healthcare Limited has informed the Exchange about Link of Recording
Others · 29 Jul 2026, 10:40 pm
Sakar Healthcare Limited has informed the Exchange about Investor Presentation
Investor Presentation · 28 Jul 2026, 7:31 pm
Sakar Healthcare Reports Strong Q1FY27 with PAT Up 120% YoY Sakar Healthcare posted strong Q1FY27 results, with revenue at ₹7,297 lakhs, up 38% YoY, driven by new oncology market authorizations. EBITDA grew 67% YoY to ₹2,125 lakhs, with margins expanding to 29% from 24% in Q1FY26. Profit After Tax (PAT) surged 120% YoY to ₹1,028 lakhs, increasing the PAT margin to 14%. The oncology segment continues to be a key growth driver, with the company executing over 65 product contracts and securing 16 marketing authorizations globally for its oncology portfolio.
Sakar Healthcare Limited has informed the Exchange about Schedule of meet/Conference Call.
Intimation · 29 Jul 2026, 12:00 pm
Sakar Healthcare Schedules Q1 FY27 Results Conference Call Sakar Healthcare (NSE: SAKAR) will host a conference call for analysts and investors on 29th Jul'26 at 12:00 PM IST to discuss its Q1 FY27 financial results. Key company participants will include Bikramjit Ghosh (VP Strategy & Business Development) and Bharat Soni (Company Secretary). The event is organized by MUFG Intime India Private Limited. Investors can pre-register for the call to avoid wait times.
Sakar Healthcare Limited has informed the Exchange regarding a press release dated July 24, 2026, titled "Consolidated and Standalone Un-audited Financial Results for the quarter ended June 30, 2026".
Press Release · 25 Jul 2026, 1:44 am
Sakar Healthcare Q1FY27 PAT Jumps 120% on Strong Revenue and Margin Expansion Sakar Healthcare reported robust Q1FY27 results, with revenue growing 38% YoY to ₹7,297 lakhs. EBITDA increased 67% YoY to ₹2,125 lakhs, with the margin expanding from 24% to 29%. Profit After Tax (PAT) surged 120% YoY to ₹1,028 lakhs, boosting the PAT margin to 14% from 9% in Q1FY26. Growth was driven by new oncology product authorizations and strong demand. The company executed over 65 oncology contracts, developed 21 in-house APIs, and advanced regulatory filings, strengthening its long-term outlook.
Sakar Healthcare Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
Outcome · 24 Jul 2026, 5:47 pm
Sakar Healthcare Ltd - Financial Result for the Quarter ended 30th Jun'26 (Consolidated, INR Lakh) ■ Revenue: 7,297 (+38.4% YoY | +2.6% QoQ) ■ EBITDA: 2,125 (+67.2% YoY | -19.0% QoQ) ■ EBITDA Margin (%): 29.1 (+503 bps YoY | -778 bps QoQ) ■ PAT: 1,028 (+120.2% YoY | -6.7% QoQ) ■ EPS (INR): 4.62 (+119.0% YoY | -6.9% QoQ)
Sakar Healthcare Limited has informed the Exchange about the intimation of Board Meeting for taking on record Unaudited Financial Results for the quarter ended on 30th June, 2026 and other matter.
Intimation · 24 Jul 2026, 5:30 am
Sakar Healthcare Board Meeting to Approve Q1FY27 Results on 24-Jul-26 Sakar Healthcare Limited (SAKAR) has scheduled a Board of Directors meeting on 24th Jul'26 to consider and approve the unaudited financial results for the quarter ended 30th Jun'26. The agenda also includes other unspecified matters. In line with regulations, the trading window for designated persons remains closed until 48 hours after the results are declared, as previously communicated on 26th Jun'26.
SAKAR HEALTHCARE LIMITED has informed the Exchange about Board Meeting to be held on 24-Jul-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Quarterly ended June 2026 .
Intimation · 24 Jul 2026, 5:30 am
Sakar Healthcare Board to Review Q1FY27 Results on 24-Jul'26 Sakar Healthcare's Board of Directors will meet on 24-Jul'26 to consider and approve the company's unaudited financial results for the quarter ending Jun'26. The outcome of this meeting will provide the first look at the company's performance for the new fiscal year.